FDA Grants Breakthrough Status to Alkermes New Narcolepsy Drug
FDA grants Breakthrough Therapy status to alixorexton for narcolepsy type 1. Clinical trials show promising results for daytime wakefulness.
/ 6 items
#ALKS↓
Avadel Gets Competing Bid from Lundbeck
Avadel Pharmaceuticals receives unsolicited $23/share offer from Lundbeck, competing with existing $20/share Alkermes deal. Board reviewing superior proposal.
Truist Says Alkermes’ Alixorexton Data Lacks Detail Despite Phase 2 Success
Truist comments on Alkermes’ Phase 2 Vibrance-2 trial of alixorexton in narcolepsy type 2, noting "limited" details but strong patient engagement and maintaining a Buy rating with a $50 target.
Orexin Drug Race: Centessa Shows Promise, Alkermes Stands Strong
Centessa has great sleep drug data, easing daytime sleepiness. Alkermes stock jumped 7% as its competing drug is still strong.
Alkermes to Acquire Avadel for Up to $2.1 Billion, Expanding Into Sleep Medicine Market
Alkermes (ALKS) announces $2.1B acquisition of Avadel Pharmaceuticals (AVDL) to gain approved narcolepsy drug Lumryz and enter the growing sleep medicine market. Deal expected Q1 2026.
A New Dawn for Narcolepsy: Understanding Alixorexton's Promise
Alixorexton, a new drug for narcolepsy type 1, shows great promise. It helps patients stay awake longer (28 mins, considered normal), reduces sleepiness, cataplexy, fatigue, and improves focus. It's well-tolerated and moving to Phase 3, signaling a potential new era for treatment.